Skip to main content

Table 3 Timeline changes in cytokeratin + cells in patients’ PBMCs

From: Revealing role of epigenetic modifiers and DNA oxidation in cell-autonomous regulation of Cancer stem cells

In vitro Treatment

Cytokeratin %

EpCam %

Oct4%

Tet2%

5hmC %

Remarks

Patient 9

MNCs with vehicle showed reduced CSCs. Double treatment led to enhanced DNA methylation

Vehicle

.06

.02

.02

0

0

Carboplatin

.34

.29

.01

.06

.06

Carboplatin + Azacitidine

.33

.13

.04

.07

.19

Patient 10

Treatment of triple negative BCCs reduced DNA hydroxylase

Vehicle

.48

.04

.03

.03

.39

Carboplatin

.2

.04

.06

.02

.06

Carboplatin + Azacitidine

.45

.15

.04

.05

.06

  1. Table showed the results of Patients 9 and 10, untreated and treated with the shown drugs. Mononuclear cells (MNCs) were treated with carboplatin and/or azacitidine. At day 7, the cells were analyzed by phenotype with the two panel antibodies described in Table 2
Back to article page

Cell Communication and Signaling

ISSN: 1478-811X